Herbal Drugs Used in the Management of Alzheimer’s Disease: A Comprehensive Review of Phyto-Therapeutic Approaches, Mechanisms and Future Perspectives

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, characterized by progressive impairment of memory, cognition, behavior and activities of daily living. Its pathogenesis is multifactorial and involves amyloid-β (Aβ) aggregation, hyperphosphorylation of tau protein, cholinergic dysfunction, oxidative stress, mitochondrial impairment, neuroinflammation, synaptic dysfunction and neuronal loss.¹–⁴ Although conventional pharmacotherapy includes acetylcholinesterase inhibitors, memantine and, more recently, disease-modifying anti-amyloid antibodies, limitations such as modest symptomatic efficacy, adverse effects, treatment burden, cost and the need for careful patient selection continue to stimulate research into complementary therapeutic approaches.⁵–⁷ Medicinal plants contain diverse bioactive compounds capable of acting simultaneously on several pathological pathways. Important herbal candidates investigated in AD include Ginkgo biloba, Bacopa monnieri, Withania somnifera, Curcuma longa, Crocus sativus, Salvia officinalis, Melissa officinalis, Panax ginseng, Centella asiatica, Huperzia serrata, Nigella sativa and Camellia sinensis.⁸–¹² Their reported activities include acetylcholinesterase inhibition, antioxidant and anti-inflammatory effects, modulation of amyloid and tau pathology, mitochondrial protection, enhancement of neurotrophic signaling and improvement of synaptic plasticity. Recent systematic reviews of human studies suggest that Ginkgo biloba, Crocus sativus, Salvia officinalis and Melissa officinalis have produced encouraging cognitive or behavioral findings, although study quality, formulations, doses and treatment duration vary substantially.¹³,¹⁴ Future development should focus on standardized phytopharmaceutical preparations, pharmacokinetic optimization, advanced drug-delivery systems, validated biomarkers, well-designed randomized clinical trials and rational combination therapy. Herbal medicines therefore represent a promising research avenue, but current evidence does not justify considering them universally equivalent or superior to established pharmacological treatment. Keywords: Alzheimer’s disease; herbal drugs; curcumin; Ginkgo biloba; amyloid-β; tau; cognitive impairment.

Authors

Publication Details

Journal
Journal of Drug Delivery and Therapeutics
Published
2026-11-15
DOI
https://doi.org/10.22270/jddt.v16i11.8067
Primary Topic
Medicinal Plants and Neuroprotection
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Herbal Drugs Used in the Management of Alzheimer’s Disease: A Comprehensive Review of Phyto-Therapeutic Approaches, Mechanisms and Future Perspectives

Girish Kumar Yadav, Rambabu Sharma, Amarjeet Singh
Journal of Drug Delivery and Therapeutics
Medicinal Plants and Neuroprotection
article

Herbal Drugs Used in the Management of Alzheimer’s Disease: A Comprehensive Review of Phyto-Therapeutic Approaches, Mechanisms and Future Perspectives

Girish Kumar Yadav, Rambabu Sharma, Amarjeet Singh
article en

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, characterized by progressive impairment of memory, cognition, behavior and activities of daily living. Its pathogenesis is multifactorial and involves amyloid-β (Aβ) aggregation, hyperphosphorylation of tau protein, cholinergic dysfunction, oxidative stress, mitochondrial impairment, neuroinflammation, synaptic dysfunction and neuronal loss.¹–⁴ Although conventional pharmacotherapy includes acetylcholinesterase inhibitors, memantine and, more recently, disease-modifying anti-amyloid antibodies, limitations such as modest symptomatic efficacy, adverse effects, treatment burden, cost and the need for careful patient selection continue to stimulate research into complementary therapeutic approaches.⁵–⁷ Medicinal plants contain diverse bioactive compounds capable of acting simultaneously on several pathological pathways. Important herbal candidates investigated in AD include Ginkgo biloba, Bacopa monnieri, Withania somnifera, Curcuma longa, Crocus sativus, Salvia officinalis, Melissa officinalis, Panax ginseng, Centella asiatica, Huperzia serrata, Nigella sativa and Camellia sinensis.⁸–¹² Their reported activities include acetylcholinesterase inhibition, antioxidant and anti-inflammatory effects, modulation of amyloid and tau pathology, mitochondrial protection, enhancement of neurotrophic signaling and improvement of synaptic plasticity. Recent systematic reviews of human studies suggest that Ginkgo biloba, Crocus sativus, Salvia officinalis and Melissa officinalis have produced encouraging cognitive or behavioral findings, although study quality, formulations, doses and treatment duration vary substantially.¹³,¹⁴ Future development should focus on standardized phytopharmaceutical preparations, pharmacokinetic optimization, advanced drug-delivery systems, validated biomarkers, well-designed randomized clinical trials and rational combination therapy. Herbal medicines therefore represent a promising research avenue, but current evidence does not justify considering them universally equivalent or superior to established pharmacological treatment. Keywords: Alzheimer’s disease; herbal drugs; curcumin; Ginkgo biloba; amyloid-β; tau; cognitive impairment.

Journal of Drug Delivery and TherapeuticsVol. 16(11)
Medicinal Plants and Neuroprotection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon